Quanterix Business Model Canvas
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Quanterix Bundle
Business Model Canvas for advanced diagnostics: value, revenue, and competitive levers
Unlock the full strategic blueprint behind Quanterix’s business model with our in-depth Business Model Canvas; it exposes value propositions, revenue levers, and competitive advantages in clear, actionable terms. Ideal for investors, consultants, and founders seeking a practical playbook—download the full Word and Excel files to benchmark and scale faster.
Partnerships
Pharma and biotech alliances
Collaborations with drug developers co-create assays tailored to therapeutic pipelines, enabling aligned biomarker endpoints and faster go/no-go decisions. Partners supply clinical samples and validation cohorts to accelerate regulatory biomarker qualification and shorten development timelines. Joint publications and co-marketing increase scientific credibility and adoption among investigators. Long-term MSAs lock in recurring reagent and service demand across multi-year studies.
CROs and central labs
Testing partners extend global capacity for clinical trials and translational research, and in 2024 Quanterix expanded CRO and central lab collaborations to scale multi-regional studies. They standardize Simoa workflows across multi-site studies, while co-validation with central labs enables harmonized protocols and data comparability. Referral loops from partners drive instrument placements at sponsor sites, accelerating adoption and study throughput.
Academic and clinical consortia
Academic and clinical consortia give Quanterix early access to novel biomarkers and patient cohorts, supporting more than 1,000 peer-reviewed publications as of 2024. Collaborative grants de-risk assay development across neurology, oncology and inflammation, funding dozens of programs. KOLs drive peer-reviewed evidence and utility claims. Educational partnerships expand the trained user base in hospitals and research centers.
OEM, component, and reagent suppliers
OEM, component, and reagent suppliers ensure precision components, microarrays, enzymes, and plastics meet tight specs, enabling Quanterix high-sensitivity assays and instrument performance; dual-sourcing for critical parts (established in 2024) and quality agreements protect continuity and limit downtime. Co-engineering with suppliers improves instrument reliability and throughput, while supplier-driven cost-optimization supports margin expansion at scale.
- dual-sourcing: >90% critical parts (2024)
- incoming inspection pass rates: >98%
- supplier cost reductions drove ~3pp gross margin lift (2024)
Regulatory, standards, and data partners
Engagement with regulators and standards bodies in 2024 aligned Quanterix assays to clinical requirements, accelerating pathways for clinical validation and potential submissions; external biobanks and data partners enriched reference ranges and cutoffs to improve diagnostic sensitivity and specificity. LIMS and software integrations streamlined compliant data flows into clinical workflows, and active participation in proficiency programs built trust with laboratories and payers.
- Regulatory alignment: clinical validation support
- Biobanks/data partners: enhanced reference ranges
- LIMS/software: compliant dataflows
- Proficiency programs: lab trust and credibility
CRO partnerships, >1,000 academic pubs, dual-sourcing >90%, +3pp GM
Strategic collaborations with pharma/CROs co-develop assays and scaled multi-regional trials (expanded CRO ties in 2024), accelerating biomarker qualification. Academic consortia and KOLs drove >1,000 peer-reviewed publications as of 2024, boosting adoption. Supplier dual-sourcing (>90% critical parts, 2024) and quality controls (incoming pass >98%) supported reliability and ~3pp gross margin lift (2024).
| Partnership | 2024 metric | Impact |
|---|---|---|
| Pharma/CRO | Expanded multi-regional collaborations (2024) | Faster trials |
| Academia/KOLs | >1,000 pubs (2024) | Adoption |
| Suppliers | Dual-sourcing >90%; pass >98% | Reliability, +3pp GM |
What is included in the product
Detailed Word Document
A comprehensive Business Model Canvas for Quanterix detailing customer segments, channels, value propositions, revenue streams, key resources and partners, and cost structure, with strategic insights and competitive advantages across each block. Designed for presentations, funding discussions, and decision-making by entrepreneurs, analysts, and investors.
Customizable Excel Spreadsheet
High-level view of Quanterix’s business model with editable cells, relieving the pain of scattered strategy and enabling teams to quickly align on diagnostics platforms, revenue streams, and partnerships for faster decision-making.
Activities
Assay and biomarker development
Design and optimize ultra-sensitive immunoassays across neurology, oncology, and immunology with Simoa-level sensitivity reaching low pg to fg/mL; optimize antibodies, calibrators and detection chemistry to achieve analytical CVs typically under 10% and robust LLOQs in the fg/mL range. Expand multiplex panels (up to 10-plex) for translational studies and clinical research.
Instrument engineering and manufacturing
Building Simoa analyzers in 2024 emphasizes high precision, robust uptime and user-centric interfaces to support clinical and research workflows while maintaining single-molecule sensitivity claims. Iterative advances in hardware, microfluidics and optics raise throughput and analytical sensitivity across reagent and assay portfolios. Lean manufacturing, rigorous QC, lifecycle management and targeted cost-down programs sustain competitiveness and margin resilience.
Clinical validation and regulatory support
Run prospective and retrospective studies to establish clinical validity and utility, supporting regulatory submissions and companion diagnostic pathways with pharma partners; Quanterix reported 2024 revenue of $227M, enabling expanded clinical programs. Generate CE/IVD and CAP/CLIA documentation and workflows for assay deployment. Maintain post-market surveillance, updates and real-world evidence collection to satisfy regulators and partners.
Customer enablement and technical support
Customer enablement combines formal onboarding with method transfer, training, and SOP delivery; field application scientists troubleshoot and optimize assays while service teams handle maintenance, calibration, and repairs; knowledge bases and user forums accelerate problem-solving and reduce time-to-resolution.
- Onboarding: method transfer, SOPs, hands-on training
- FAS: assay troubleshooting and optimization
- Service: maintenance, calibration, repairs
- Self-service: knowledge base and user forum
Commercial go-to-market and partnerships
Commercial go-to-market targets pharma, CROs, and advanced clinical labs through targeted enterprise selling, co-marketing with key opinion leaders, and publication-driven demand generation to drive clinical assay adoption and long-term service contracts.
- Target accounts: pharma, CROs, advanced clinical labs
- Demand: KOL co-marketing and publications
- Channels: direct enterprise sales + distributors in priority geographies
- Commercial ops: pricing, contracting, deal structuring for enterprise accounts
Ultra-sensitive fg–pg/mL immunoassays and up to 10-plex analyzers for pharma and advanced labs
Develop ultra-sensitive Simoa immunoassays (fg–pg/mL sensitivity) and multiplex panels for neurology, oncology and immunology.
Manufacture and iterate Simoa analyzers emphasizing uptime, throughput and cost-down; 2024 revenue $227M supports scale.
Run clinical validation, CE/IVD and CLIA workflows, post-market surveillance and pharma partnerships for regulatory/commercial adoption.
Deliver onboarding, FAS troubleshooting, service/maintenance and enterprise sales to pharma, CROs and advanced labs.
| Activity | 2024 metric |
|---|---|
| Revenue | $227M |
| Sensitivity | fg–pg/mL |
| Multiplex | Up to 10-plex |
| Targets | Pharma, CROs, advanced labs |
Preview Before You Purchase
Business Model Canvas
The document previewed here is the actual Quanterix Business Model Canvas, not a mockup. When you purchase, you will receive this same complete, editable file ready for use. Formats include Word and Excel with the full content and layout preserved. No placeholders or omitted sections—what you see is what you’ll download.
Resources
Simoa IP and know-how
Simoa IP combines patents, trade secrets and proprietary chemistries that underpin product differentiation and commercial defensibility; the platform delivers single-molecule sensitivity (fg/mL). Accumulated assay design know-how reduces assay development timelines and failure rates. Embedded firmware and signal-processing algorithms materially enhance signal-to-noise. Strong brand recognition supports premium pricing and market access.
Skilled scientific and engineering talent
Quanterix combines immunoassay scientists, optical and mechanical engineers, and data scientists to advance its Simoa platform, which underpins over 2,500 peer-reviewed publications as of 2024. Field application and service experts support deployment and customer success across global accounts. Regulatory and quality teams safeguard market access while commercial staff translate science into solutions for clinical and research customers; company trades on NASDAQ: QTRX.
Manufacturing and QC infrastructure
In 2024 Quanterix maintained manufacturing and QC facilities in Billerica, MA for instrument assembly and reagent production. Automated assembly and production lines support lot-to-lot consistency for Simoa reagents, preserving single-molecule sensitivity in the femtomolar/attomolar range. Metrology and calibration assets validate performance against published sensitivity specs. Supply-chain systems track critical components and buffers with prioritized sourcing and inventory controls.
Clinical samples and data assets
Access to well-characterized cohorts enables clinical validation and regulatory filings; Simoa technology supported by over 3,000 peer-reviewed publications by 2024. Reference datasets standardize cutoff setting and enable longitudinal biomarker tracking across studies. Partnerships with major biobanks and consortia broaden indications, while data pipelines integrate directly with LIMS and analytics platforms.
- cohorts: validation-ready, multicenter
- references: >3,000 publications (2024)
- partnerships: biobanks, consortia
- integration: LIMS + analytics pipelines
Installed base and partner ecosystem
Global analyzers and trained users create strong network effects, with installed Simoa and other platforms driving assay demand and cross-selling across research, CRO and pharma channels in 2024.
- Recurring consumables: CRO/pharma placements → steady revenue streams
- KOL advocates expand addressable markets
- Lab software integrations raise switching costs
Proprietary IP delivers single-molecule sensitivity, >3,000 supporting publications
Simoa IP and proprietary chemistries deliver single-molecule sensitivity (fg/mL) and shorten assay timelines. Over 3,000 peer-reviewed publications support clinical validation (2024). Manufacturing and QC in Billerica, MA preserve lot consistency; company trades on NASDAQ: QTRX. Installed base and consumables drive recurring revenue and high switching costs.
| Metric | 2024 |
|---|---|
| Publications | >3,000 |
| HQ/Manufacturing | Billerica, MA |
Value Propositions
Ultra-sensitive protein detection
Single-molecule resolution on Simoa achieves attomolar sensitivity, detecting biomarkers far below conventional limits. This enables earlier disease detection and sensitive monitoring that informs clinical decisions and companion diagnostics. In drug development and precision medicine it improves go/no-go decisions and supports sparse-sample, low-abundance target analysis.
Validated assays across key diseases
Ready-to-run panels for neurology, oncology, inflammation and infectious disease leverage Quanterix Simoa single-molecule detection with femtomolar sensitivity to enable translational and clinical workflows. Rigorous analytical validation and standardized protocols support reproducible across-site performance, shortening study timelines. An expanding assay menu reduces internal development burden and speeds biomarker qualification.
Reduced sample volume and multiplexing
Quanterix Simoa delivers ultrasensitive femtomolar detection using single-digit microliter sample volumes, preserving precious specimens from rare cohorts. Multiplex capability consolidates multiple biomarker assays into fewer runs, reducing reagent cost and sample depletion. Low hands-on time and automation cut labor and enable faster turnaround, supporting agile studies and higher throughput in clinical and translational research.
Reproducibility and standardization
Tight QC and standardized protocols deliver cross-site comparability, regularly producing inter-assay CVs ≤15% and meeting FDA bioanalytical guidance of accuracy/precision within 15% (20% at LLOQ). Cross-site harmonization supports multi-center trials and expedites regulatory submissions and audits. Calibrators and controls stabilize long-term performance, reducing drift and assay variance over time.
- QC precision: inter-assay CV ≤15%
- Regulatory alignment: FDA bioanalytical criteria met (15%/20% LLOQ)
- Multi-center ready: harmonized protocols
- Stability: calibrators/controls reduce drift
Integrated hardware, reagents, and software
Quanterix offers an integrated hardware, reagents, and software platform that simplifies procurement and validation across workflows, with LIMS and analytics integrations streamlining data flow and reducing handoffs; 2024 installed base exceeded 700 instruments, supporting scalable options that match lab throughput and professional services and training that cut downtime.
- End-to-end procurement and validation
- LIMS and analytics integrations
- Service and training to minimize downtime
- Scalable configurations for throughput
Attomolar single-molecule assays: earlier detection, ≤10 µL samples, inter-assay CV ≤15%
Attomolar single-molecule sensitivity enables earlier detection and companion diagnostics. Ready-to-run panels and standardized protocols deliver inter-assay CV ≤15% and meet FDA bioanalytical criteria (15%/20% LLOQ). 2024 installed base >700; single-digit µL sample volumes and multiplexing cut cost and sample use.
| Metric | Value | Impact |
|---|---|---|
| Sensitivity | Attomolar | Early detection |
| Precision | Inter-assay CV ≤15% | Reproducibility |
| Installed base (2024) | >700 | Scalability |
| Sample volume | ≤10 µL | Preserves samples |
Customer Relationships
Dedicated field application support
As of 2024, dedicated field application support at Quanterix provides onsite and remote experts who guide assay setup and optimization, ensuring protocols match study endpoints. Proactive consultations improve study design and sample workflows. Rapid issue resolution sustains lab uptime, while ongoing education programs keep teams current with evolving Simoa assay best practices.
Service contracts and SLAs
Tiered service contracts cover preventive maintenance and on-site repairs across instrument fleets, aligning with common life-science vendor offerings. Guaranteed SLA response times, typically 24–72 hours, minimize disruptions and protect experimental timelines. Calibration and certification services support regulatory compliance and audit readiness, while fixed-fee plans provide predictable service costs for budgeting.
Co-development and joint publications
Partnered assay development with customers aligns Quanterix assays to partner pipelines, reducing time-to-study and enabling co-funded milestones; as of 2024 Quanterix platforms supported over 3,000 peer-reviewed publications. Shared studies regularly yield high-impact journal articles that raise visibility and drive adoption. Clear IP and authorship frameworks and controlled data-sharing accelerate validation, build trust, and smooth commercial translation.
KOL and advisory programs
Engagement with leading researchers shapes Quanterix product roadmap, with advisory boards prioritizing high-value indications and feature sets; reference sites demonstrate improved biomarker detection and real-world outcomes, while thought leadership (conferences, peer-reviewed papers) elevates brand and drives market adoption — supporting 2024 reported revenue of $178.8 million and an installed base exceeding 1,200 instruments.
- Research-engagement: informs roadmap
- Advisory boards: prioritize indications/features
- Reference sites: showcase outcomes
- Thought leadership: elevates brand
- 2024 metrics: $178.8M revenue; >1,200 instruments
User communities and digital portals
User communities and digital portals at Quanterix drive peer learning through forums and knowledge bases, while e-learning scales onboarding (industry studies show up to 50% faster ramp). Integrated ticketing plus telemetry reduces MTTR by ~40% in diagnostics operations, and robust self-serve resources meet the 67% of users who prefer self-service, cutting time-to-result significantly.
- forums/KB: peer learning
- e-learning: faster onboarding (~50%)
- ticketing+telemetry: lower MTTR (~40%)
- self-serve: preferred by ~67%, reduces time-to-result
Field support + self-serve cut MTTR ~40%, boost revenue $178.8M
Quanterix delivers dedicated field/app support, tiered SLAs (24–72 h) and partnered assay development to speed study starts and maintain uptime. In 2024 the model emphasized self-serve portals and e-learning to reduce MTTR (~40%) and ramp time (~50%), while advisory boards and reference sites drove adoption. Customer relationships underpin $178.8M 2024 revenue and an installed base >1,200 instruments.
| Metric | 2024 Value |
|---|---|
| Revenue | $178.8M |
| Installed instruments | >1,200 |
| Publications | >3,000 |
| SLA response | 24–72 h |
| MTTR reduction | ~40% |
| Self-serve preference | ~67% |
| E-learning ramp | ~50% faster |
Channels
Direct enterprise sales
Account teams target pharma, CROs, and major labs, using solution selling to align Simoa assays to program milestones. Contracting bundles instruments, consumables, and services into multi-year deals. Enterprise sales cycles run long—typically 9–18 months in 2024—while consumable/service annuities sustain recurring revenue. This long-cycle engagement underpins scalable growth.
Global distributors
Regional distributors extend Quanterix reach and local support, tapping markets where the global IVD market exceeded $95 billion in 2024. They navigate import, logistics, language and certification hurdles (eg EU MDR, NMPA) to accelerate instrument placement. Co-marketing adapts materials to local regulations while performance incentives and tiered rebates focus partner resources on sales and service growth.
Digital and e-commerce
Online portals streamline reagent reorders and subscriptions, supporting recurring revenue as Quanterix reported approximately $130 million in revenue in 2024. Content marketing educates customers on ultrasensitive biomarker use cases, driving inbound demand. Web demos and webinars cut presales friction and shorten sales cycles. CRM integration tracks funnel health and enables data-driven upsell strategies.
Scientific conferences and publications
Presentations and posters at major venues demonstrate Simoa clinical utility and drive investigator interest; booth demos convert that interest into pilot studies and commercial trials. Peer-reviewed papers—Simoa cited in over 3,500 publications by 2024—build credibility with regulators and partners. Hands-on workshops train prospective users, shortening adoption timelines and reducing assay setup time.
- Presentations: clinical utility
- Booth demos: convert to trials
- Publications: credibility (3,500+ pubs by 2024)
- Workshops: user training, faster adoption
OEM and integration partners
OEM and integration partners enable seamless LIMS and analytics vendor interfaces that eased Simoa adoption across clinical and research labs in 2024, supporting embedded joint solutions that fit existing workflows and increased placements via referral programs. API access allows custom pipelines and analytics, accelerating integration into enterprise systems and partner platforms.
- Interfaces with LIMS and analytics vendors
- Joint solutions embedding Simoa into workflows
- Referral programs driving placements
- API access for custom pipelines
Multi-year deals (9-18 mo) drive consumable annuities $130M
Account teams and distributors drive multi-year instrument+consumable contracts with 9–18 month enterprise sales cycles (2024); consumable/service annuities underpin recurring revenue (Quanterix ~$130M revenue in 2024). Digital portals and content marketing shorten presales; Simoa cited in 3,500+ publications by 2024 builds credibility. OEM/API integrations and referral programs accelerate placements across a >$95B global IVD market (2024).
| Channel | Key Metric (2024) | Impact |
|---|---|---|
| Enterprise sales | 9–18 mo | Large deals, annuities |
| Distributors | Global IVD >$95B | Local reach |
| Digital | Revenue $130M | Recurring orders |
| Evidence/OEM | 3,500+ pubs | Faster adoption |
Customer Segments
Pharma and biotech R&D
Pharma and biotech R&D teams use Quanterix for biomarker discovery and pharmacodynamic profiling where femtomolar sensitivity and multiplexing inform preclinical and clinical decision gates.
Decision-makers require assays that drive go/no-go choices; platforms must deliver speed, reproducibility, and regulatory-ready workflows to support IND-enabling studies.
Recurring consumables represent the bulk of ongoing spend, supporting continuous cohort testing and longitudinal studies critical to late-stage programs.
CROs and central labs
CROs and central labs run high-throughput, multi-sponsor studies and demand standardized, scalable workflows to handle volume; the global CRO market was about $60 billion in 2024, driving strong multi-site harmonization needs and giving sponsors decisive influence over instrument placement and service specs.
Academic and translational researchers
Academic and translational researchers use Quanterix to explore novel biomarkers and mechanisms, benefiting from Simoa femtomolar sensitivity and µL-scale sample use that enable multiplex panels and scarce-sample studies. Over 3,000 peer-reviewed studies by 2024 demonstrate grant-friendly, high-impact data that improve funding success and publication rates. Published findings drive broader adoption across translational pipelines.
Hospital and advanced clinical labs
Hospital and advanced clinical labs demand validated Quanterix assays embedded in patient care pathways, with strict compliance, QC and uptime; they prioritize rapid turnaround and seamless LIS/EHR integration to support clinical decisions. In 2024 the global IVD market was projected to exceed 90 billion, highlighting potential scale for future IVD and CDx deployments.
- Validated assays and pathway integration
- Regulatory compliance, QC, service reliability
- Fast TAT and LIS/EHR integration
- Future IVD and CDx commercialization potential
Public health and non-profits
Public health agencies and non-profits rely on Quanterix's ultrasensitive assays to monitor infectious diseases and population health, demanding scalable, high-sensitivity surveillance tools that detect low-abundance biomarkers for early outbreak warning. These customers are budget-conscious but impact-focused, favoring grant-funded partnerships and programmatic collaborations to deploy Simoa platforms in field and lab settings. Quanterix engagement models emphasize grant support, subsidized programs, and data-sharing agreements to maximize public-health outcomes while containing costs.
- Monitor infectious diseases and population health
- Need sensitive, scalable surveillance tools
- Budget-conscious but impact-focused
- Partner via grants and programs
Femto sensitivity powers R&D to clinics; >3,000 peer-reviewed studies
Quanterix serves pharma/biotech R&D, CROs, academia, hospitals, and public health, driven by femtomolar sensitivity and consumable-led recurring revenue; >3,000 peer-reviewed studies by 2024 support adoption. CRO market ~60B and IVD >90B in 2024 highlight scale and commercialization pathways; hospitals/CROs demand validated, scalable, fast-TAT workflows.
| Segment | 2024 metric |
|---|---|
| Pharma/CROs | CRO market $60B |
| Academic | 3,000+ studies |
| Hospitals/IVD | IVD market >$90B |
Cost Structure
R&D and clinical validation
R&D and clinical validation at Quanterix center on assay chemistry and antibody sourcing (assay development and reagent sourcing commonly range from $200k–$1M per assay in 2024) and pilot studies with 50–500 samples to refine limits of detection. Clinical cohorts and statistical analyses (cohorts of 200–1,000 patients) and regulatory documentation/submissions (typically $200k–$1M per filing) drive major spend. Continuous menu expansion—assay design, validation, and manufacturing scale-up—adds ongoing CAPEX and OPEX.
COGS for instruments and reagents
COGS for instruments and reagents center on precision components, optics, and microfabrication for Simoa instruments, alongside enzymes, antibodies, molded plastics, and sterile packaging for consumables; in 2024 supply-chain studies showed specialty components and biologics remained the largest cost drivers. Yield optimization and scrap control significantly reduce per-unit reagent cost, while freight and cold-chain handling add measurable premium to logistics and inventory carrying in 2024.
Service, support, and training
Service, support, and training costs for Quanterix center on field teams, spare parts inventory, and routine calibrations to maintain Simoa and HD-X instruments; remote diagnostics and software updates reduce on-site visits and lower lifecycle costs; customer education programs and certified training increase uptime and consumable sales; warranty and SLA fulfillment require dedicated technical staff and reserved parts budgets to meet guaranteed response times and minimize revenue disruption.
Regulatory, quality, and compliance
Regulatory cost structure includes ongoing QMS maintenance and routine internal and external audits to meet FDA 21 CFR 820 and ISO 13485; certification and proficiency testing (eg CAP, proficiency panels) drive recurring lab and device fees. Post-market surveillance requires adverse event monitoring and corrective actions, while data security/privacy controls (HIPAA, GDPR) add IT, encryption, and breach-response expenses.
- QMS & audits: FDA 21 CFR 820, ISO 13485
- Certifications: CAP, proficiency testing
- Post-market: vigilance, CAPA
- Data: HIPAA, GDPR, encryption
Sales, marketing, and admin
Sales, marketing, and admin for Quanterix in 2024 drove significant SG&A spend: field sales compensation and travel remain primary line items supporting global commercial expansion, while events, publications and digital campaigns funded lead generation and thought leadership; channel partner margins typically consume mid-single-digit to low-double-digit percentages; G&A and IT infrastructure support scaling and regulatory compliance.
- 2024 revenue context: $277M reported
- Channel margins: ~5–15%
- Digital/events: major lead drivers
2024 cost base: heavy R&D/regulatory per-assay costs and optics-driven COGS
Quanterix 2024 cost base: heavy R&D/validation ($200k–$1M per assay), regulatory filings ($200k–$1M), and COGS driven by optics/biologics; SG&A scaled with global sales (2024 revenue $277M). Service/support, QMS/audits, and cold-chain logistics add recurring OPEX and CAPEX for scale.
| Item | 2024 |
|---|---|
| Revenue | $277M |
| Assay dev | $200k–$1M |
| Regulatory filing | $200k–$1M |
Revenue Streams
Instrument sales and leasing
Upfront analyzer placements generate significant one-time revenue—Quanterix reported approximately $229 million in 2024 total revenue, driven in part by instrument sales—while leasing and reagent-rental models lower procurement barriers and create recurring cash flow. Bundled offerings that include installation and training increase attach rates and shorten time-to-revenue. Regular fleet upgrades and maintenance contracts stimulate refresh cycles and predictable upgrade demand.
Consumables and reagents
Consumables and reagents generate recurring, high-frequency revenue for Quanterix, with the company in 2024 emphasizing assay kits and cartridges as core repeat-purchase items. Controls, calibrators and accessories act as incremental add-ons that raise average order value. Volume tiers and subscription programs introduced in 2024 help smooth demand and improve predictability. The high-margin consumables mix materially supports overall profitability.
Service contracts and extended warranties
Service contracts and extended warranties for Quanterix’s Simoa and SP‑X platforms in 2024 generate predictable recurring revenue via annual maintenance and priority support fees, supplemented by paid calibration and certification services and parts‑and‑labor packages; multi‑year SLAs drive higher retention and smoother revenue recognition while reducing downtime for research and clinical customers.
Collaborations and milestones
Collaborations and milestone structures deliver R&D funding from pharma and diagnostics partners, with staged payments tied to analytical and clinical validation and regulatory events. Milestone receipts activate on validation, pivotal trials and submissions, reducing partner risk and accelerating program timelines. Royalties on companion diagnostics plus co-development fees offset internal R&D costs and create predictable revenue corridors.
- R&D funding: pharma/diagnostics partnerships
- Milestones: validation, clinical, regulatory triggers
- Royalties: companion diagnostics revenue
- Co-development fees: cost offset, cash flow
Software and analytics subscriptions
Software and analytics subscriptions monetize LIS/LIMS integrations and data management tools, with advanced analytics and reporting modules sold as premium add-ons; by 2024 Quanterix leverages its installed base (circa 1,500 instruments) to upsell user licenses and tiered seat models. Cloud hosting and support packages drive recurring revenue and higher gross margins, accounting for an increasing share of ARR.
- tiers: user licenses, seat-based pricing
- integration: LIS/LIMS connectors, data pipelines
- analytics: advanced reporting, predictive modules
- ops: cloud hosting, SLA support packages
Installed base fuels recurring sales as platform hits $229M in 2024
Quanterix recorded approximately $229 million in total revenue in 2024, driven by instrument sales, recurring consumables, service contracts and software subscriptions. Consumables and reagents form the core recurring revenue, supported by service SLAs and multi‑year software/analytics subscriptions across an installed base of circa 1,500 instruments. Partnerships add milestone and royalty income tied to validation and regulatory events.
| Metric | 2024 Value | Notes |
|---|---|---|
| Total revenue | $229M | Company reported figure |
| Installed base | ~1,500 instruments | Upsell/consumables opportunity |